ALDR Alder Biopharmaceuticals Inc.

Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences

Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences

BOTHELL, Wash., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that members of the management team will provide a business overview and update at the Wells Fargo Securities 2019 Healthcare Conference at 2:25 p.m. ET on Wednesday, September 4, 2019 in Boston, MA and at the Morgan Stanley 17th Annual Global Healthcare Conference at 4:05 p.m. ET on Tuesday, September 10, 2019 in New York, NY.

The presentations will be webcast live on the Events & Presentations page of the Investors section of Alder's website at , or by following the links below in your web browser. An archived replay of the webcasts will be available on Alder's website for at least 30 days after the live event concludes.

  • Wells Fargo:

     
  • Morgan Stanley:

About Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming migraine treatment through the discovery, development and commercialization of novel therapeutic antibodies. The company’s mission is to forever change migraine treatment and give people with migraine their lives back. In 2019, Alder was ranked 19th among the top 100 fastest growing companies in Seattle by Growjo.

Eptinezumab, Alder’s lead product candidate for migraine prevention, is an investigational monoclonal antibody (mAb) that is delivered via IV and designed for 100% bioavailability with high specificity and strong binding for suppression of calcitonin gene-related peptide (CGRP). If approved by the U.S. Food and Drug Administration, it will be the first IV therapy for migraine prevention. Alder is also developing ALD1910, a preclinical mAb designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP) for migraine prevention. For more information, please visit .

Investor Relations Contact:                                        

Sarah McCabe

Stern Investor Relations, Inc.

212-362-1200

Media Contact:

Ashley Cadle

TogoRun

310-463-0143

EN
28/08/2019

Underlying

ALDRAlder Biopharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Alder Biopharmaceuticals Inc.

 PRESS RELEASE
Free
ALDR Alder Biopharma...

Lundbeck and Alder BioPharmaceuticals announce updated information in ...

Lundbeck and Alder BioPharmaceuticals announce updated information in the tender offer materials filed with SEC Updated tender offer materials provide additional summary information regarding existing Lundbeck offer terms, including existing CVR terms, and additional information regarding existing Alder director and officer share ownership Offer terms remain unchanged from commencement, with Lundbeck offering Alder stockholders upfront payment of USD 18.00 per share in cash along with one non-tradeable Contingent Value Right for USD 2.00 per share contingent on upon approval of eptinezumab ...

October 11, 2019 1 EN
 PRESS RELEASE
Free
ALDR Alder Biopharma...

Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ...

Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine ALD1910 is Alder’s first clinical candidate designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP), a novel target in treating migraine BOTHELL, Wash., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing therapeutic antibodies for the treatment of migraine, today announced dosing of the first patient in a Phase 1 clinical study to evaluate ALD1910 as a preventive trea...

October 10, 2019 1 EN
 PRESS RELEASE
Free
ALDR Alder Biopharma...

Lundbeck to acquire Alder BioPharmaceuticals – a company committed t...

Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash Enhances Lundbeck’s leading portfolio of brain disease therapies with Alder’s highly complementary intravenous (IV) therapy for migraine prevention, eptinezumabEptinezumab is an investigational monoclonal antibody (mAb) for migraine prevention targeting the calcitonin gene-related peptide (CGRP) with a PDUFA action date of 21 February 2020If approved, eptinezumab will be the first-to-market IV CGRP therapy for mi...

September 16, 2019 1 EN
 PRESS RELEASE
Free
ALDR Alder Biopharma...

Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention P...

Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society - Data analyses from clinical trials to highlight eptinezumab’s efficacy and early, sustained quality of life improvements in the prevention of chronic migraine -- Preclinical data also to be presented for ALD1910, Alder’s second candidate for migraine, demonstrating its binding and selectivity to pituitary adenylate cyclase-activating peptide - BOTHELL, Wash., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceut...

September 5, 2019 1 EN
 PRESS RELEASE
Free
ALDR Alder Biopharma...

Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listi...

Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors granted an award of 11,500 restricted stock units (“RSUs”) to a new employee under Alder’s 2018 Inducement Award Plan (the “Inducement Plan”), effective August 27, 2019. One-fourth of the RSUs will vest yearly on each an...

August 30, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch